Combination Product Firms Should Follow Specialty Pharma Model, Angiotech CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Hunter says Angiotech will follow specialty pharma model of risk, lifecycle management to achieve lasting success. The company also has started a venture capital unit and plans to vertically integrate its business.